|
End-of-day quote
New Zealand S.E.
23/09/2026
|
5-day change | 1st Jan Change | ||
| 4.300 NZD | +1.90% |
|
-0.69% | +27.22% |
| 09/09 | Aft Pharmaceuticals Limited Partners with Mark Cuban Cost Plus Drug Company to Bring Combogesic to the U.S | CI |
| 31/07 | AFT Pharmaceuticals Limited - Shareholder/Analyst Call |
| Market Cap | 45Cr 26Cr 22Cr 21Cr 19Cr 36Cr 2.45TCr 36Cr 253.62Cr 98Cr 1.25TCr 96Cr 94Cr 4.05TCr | P/E 2027 * |
22.9x | P/E 2028 * | 18.2x |
|---|---|---|---|---|---|
| Enterprise Value | 48Cr 27Cr 24Cr 23Cr 21Cr 38Cr 2.61TCr 39Cr 270.4Cr 104.83Cr 1.33TCr 102.46Cr 100.22Cr 4.32TCr | EV / Sales 2027 * |
1.58x | EV / Sales 2028 * | 1.38x |
| Free-Float |
22.37% | Yield 2027 * |
0.76% | Yield 2028 * | 0.97% |
| Markets | Quality | ||
|---|---|---|---|
New Zealand S.E.
| AFT | End-of-day quote | |
Australian S.E.
| AFP | Delayed |
Last Transcript: AFT Pharmaceuticals Limited
| 20/24/20 | Rentevrees zet Bel20 onder druk | |
| 19/24/19 | KBC uitblinker op groene beurs | |
| 19/24/19 | Brusselse beurs opent flink hoger | |
| 19/24/19 | Brussel start handelsdag vermoedelijk in het groen | |
| 19/24/19 | Hyloris gaat samenwerken met AFT Pharmaceuticals |
| 1 day | +1.90% | ||
| 1 week | -0.69% | ||
| Current month | -3.15% | ||
| 1 month | -2.71% | ||
| 3 months | +16.85% | ||
| 6 months | +26.47% | ||
| Current year | +27.22% |
| 1 week | 4.2 |  | 4.36 |
| 1 month | 4.2 | | 4.54 |
| Current year | 3.35 | | 4.85 |
| 1 year | 2.61 | | 4.85 |
| 3 years | 2.37 | | 4.85 |
| 5 years | 2.37 | | 5 |
| 10 years | 1.7 | | 5.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marree Atkinson
HRO | Human Resources Officer | - | 04/09/2012 |
Hartley Atkinson
CEO | Chief Executive Officer | - | 04/09/1997 |
Stuart Houliston
DFI | Director of Finance/CFO | - | 15/06/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
David Flacks
CHM | Chairman | - | 22/06/2015 |
Hartley Atkinson
BRD | Director/Board Member | - | 04/09/1997 |
Marree Atkinson
BRD | Director/Board Member | - | 04/09/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 03/07/25 | Buy | Founder | 2,00,000 | 0.1907% | ||
| 26/06/25 | Free | Founder | 17,755 | 0.0169% | ||
| 02/12/24 | Buy | Founder | 45 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.90% | -0.69% | +66.02% | +26.47% | 25Cr | |
| -1.68% | +0.85% | +53.62% | +107.77% | 1,04300Cr | |
| -0.43% | +0.17% | +51.62% | +67.06% | 65TCr | |
| -0.26% | +0.90% | +18.98% | +71.26% | 47TCr | |
| -0.25% | +0.19% | +36.95% | +45.54% | 35TCr | |
| +0.98% | +2.91% | +20.59% | +27.14% | 27TCr | |
| -1.91% | +2.42% | +10.41% | +11.04% | 26TCr | |
| -0.80% | +7.97% | +41.68% | +52.27% | 22TCr | |
| -1.55% | +1.92% | +31.57% | +101.15% | 19TCr | |
| -2.53% | -7.47% | -32.63% | -60.41% | 18TCr | |
| Average | -0.61% | +2.00% | +29.88% | +44.93% | 36.33TCr | |
| Weighted average by Cap. | -0.92% | +2.19% | +35.56% | +64.91% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 30Cr 17Cr 15Cr 14Cr 13Cr 24Cr 1.65TCr 24Cr 170.87Cr 66Cr 842.06Cr 65Cr 63Cr 2.73TCr | 35Cr 20Cr 17Cr 16Cr 15Cr 28Cr 1.88TCr 28Cr 194.17Cr 75Cr 956.88Cr 74Cr 72Cr 3.1TCr |
| Net income | 1.97Cr 1.12Cr 98.1L 92.22L 84.31L 1.58Cr 107.07Cr 1.59Cr 11Cr 4.29Cr 55Cr 4.2Cr 4.11Cr 176.99Cr | 2.48Cr 1.41Cr 1.24Cr 1.16Cr 1.06Cr 1.98Cr 134.89Cr 2Cr 14Cr 5.41Cr 69Cr 5.29Cr 5.17Cr 222.98Cr |
| Net Debt | 2.98Cr 1.69Cr 1.49Cr 1.4Cr 1.28Cr 2.39Cr 162.19Cr 2.4Cr 17Cr 6.5Cr 83Cr 6.36Cr 6.22Cr 268.11Cr | 2.46Cr 1.4Cr 1.23Cr 1.15Cr 1.05Cr 1.97Cr 133.71Cr 1.98Cr 14Cr 5.36Cr 68Cr 5.24Cr 5.13Cr 221.03Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | NZ$4.300 | +1.90% | 12,557 |
| 22/26/22 | NZ$4.220 | -1.40% | 89,662 |
| 21/26/21 | NZ$4.280 | -0.47% | 14,599 |
| 18/26/18 | NZ$4.300 | +0.23% | 1,14,414 |
| 17/26/17 | NZ$4.290 | -0.23% | 63,940 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AFT Stock
Select your edition
All financial news and data tailored to specific country editions
